(12) **Translation of European patent specification**

(11) **NO/EP 3531133 B1**

NORWAY

(19) NO
(51) Int Cl.
G01N 33/574 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2023.11.13
(80)	Date of The European Patent Office Publication of the Granted Patent	2023.08.23
(86)	European Application Nr.	18213926.1
(86)	European Filing Date	2015.05.20
(87)	The European Application's Publication Date	2019.08.28
(30)	Priority	2014.05.30, US, 201462005560 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 München, Tyskland Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA
(72)	Inventor	Zugmaier, Gerhard, c/o Amgen Research (Munich) GmbH Staffelseestr. 2, 81477 Munich, Tyskland Kufer, Peter, c/o Amgen Research (Munich) GmbH Staffelseestr. 2, 81477 Munich, Tyskland Alekar, Shilpa, c/o Amgen Inc One Amgen Center Drive, Thousand Oaks, CA 91320-1799, USA
(74)	Agent or Attorney	RWS, Europa House, Chiltern Park, Chiltern Hill, SL99FG CHALFONT ST PETER, Storbritannia

(54) Title **RISK-STRATIFICATION OF B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS**

(56) References Cited:

"BACKGROUND INFORMATION FOR THE PEDIATRIC SUBCOMMITTEE OF THE ONCOLOGIC DRUGS ADVISORY COMMITTEE MEETING 04 DECEMBER 2012", , 4 December 2012 (2012-12-04), XP055203294, Retrieved from the Internet: URL:http://www.fda.gov/downloads/AdvisoryC ommittees/CommitteesMeetingMaterials/Drugs /OncologicDrugsAdvisoryCommittee/UCM330210 .pdf [retrieved on 2015-07-17]

G. TALLEN ET AL: "Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90", JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 14, 12 April 2010 (2010-04-12), pages 2339-2347, XP055203293, ISSN: 0732-183X, DOI: 10.1200/JCO.2009.25.1983

G. BASSO ET AL: "Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow", JOURNAL OF CLINICAL ONCOLOGY, vol. 27, no. 31, 5 October 2009 (2009-10-05), pages 5168-5174, XP055203226, ISSN: 0732-183X, DOI: 10.1200/JCO.2008.20.8934

VISSER J H ET AL: "Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia", PEDIATRIC HEMATOLOGY AND ONCOLOGY, TAYLOR AND FRANCIS, GB, vol. 18, no. 3, 1 January 2001 (2001-01-01), pages 187-191, XP008177028, ISSN: 0888-0018, DOI: 10.1080/08880010151114804

Jan Stary ET AL: "Results of the Randomized I-BFM-SG Trial "Acute Lymphoblastic Leukemia Intercontinental-BFM 2002" in 5060 Children Diagnosed in 15 Countries on 3 Continents", , 18 September 2011 (2011-09-18), pages 397-398, XP055203224, Retrieved from the Internet: URL:https://ash.confex.com/ash/2011/webpro gram/Paper40820.html [retrieved on 2015-07-17]
DIRK NAGORSEN ET AL: "Blinatumomab: A historical perspective", PHARMACOLOGY & THERAPEUTICS, vol. 136, no. 3, 1 December 2012 (2012-12-01), pages 334-342, XP055112692, ISSN: 0163-7258, DOI: 10.1016/j.pharmthera.2012.07.013

Patentkrav

1. CD19xCD3-bispesifikt enkeltkjedeantistoff for anvendelse i en fremgangsmåte for behandling av pediatrisk B-forløper ALL hos et individ, hvori individet er et individ som har en mengde på minst 20 % blastceller per 200 telte benmargsceller i en benmargsprøve fra individet.

2. Det bispesifikke enkeltkjedeantistoffet for anvendelsen ifølge krav 1, hvori det CD19xCD3-bispesifikke enkeltkjededeantistoffet omfatter
(a) anti-CD3 CDR-er av tungkjeden vist som CD3 CDR-H1 i SEQ ID NO: 11 (RYTMH), mer foretrukket i SEQ ID NO: 11 (GYTFTRYTMH), CD3 CDR-H2 i SEQ ID NO: 12 (YINPSRGYTNYNQKFKD) og CD3 CDR-H3 i SEQ ID NO: 13 (YYDDHYCLDY); og/eller
(b) anti-CD3 CDR-er av lettkjeden vist som CD3 CDR-L1 i SEQ ID NO: 14 (RASSSVSYMN), CD3 CDR-L2 i SEQ ID NO: 15 (DTSKVAS) og CD3 CDR-L3 i SEQ ID NO: 16 (QQWSSNPLT); og/eller
(c) anti-CD19 CDR-er av tungkjeden vist som CD19 CDR-H1 i SEQ ID NO: 17 (SYWMN), mer foretrukket i SEQ ID NO: 17 (GYAFSSYWMN), CD19 CDR-H2 i SEQ ID NO: 18 (QIWPGDGDTNYNGKFKG) og CD19 CDR-H3 i SEQ ID NO: 19 (RETTTVGRYYYAMDY); og/eller
(d) anti-CD19 CDR-er av lettkjeden vist som CD19 CDR-L1 i SEQ ID NO: 20 (KASQSVDYDGDSYLN), CD19 CDR-L2 i SEQ ID NO: 21 (DASNLVS) og CD19 CDR-L3 i SEQ ID NO: 22 (QQSTEDPWT).

3. Det bispesifikke enkeltkjedeantistoffet for anvendelsen ifølge krav 1 eller 2, hvori det CD19xCD3-bispesifikke enkeltkjedeantistoffet er blinatumomab (AMG 103).

4. Det bispesifikke enkeltkjedeantistoffet for anvendelsen ifølge et hvilket som helst av kravene 1 til 3, hvori individet er et individ.